Based on the Longboard Pharmaceuticals Inc stock forecast from 8 analysts, the average analyst target price for Longboard Pharmaceuticals Inc is USD 61.97 over the next 12 months. Longboard Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Longboard Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Longboard Pharmaceuticals Inc’s stock price was USD 59.80. Longboard Pharmaceuticals Inc’s stock price has changed by +0.18% over the past week, +0.67% over the past month and +1,358.54% over the last year.
No recent analyst target price found for Longboard Pharmaceuticals Inc
No recent average analyst rating found for Longboard Pharmaceuticals Inc
Company Overview Longboard Pharmaceuticals Inc
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California. Read Less
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures ...Read More
Frequently Asked Questions About Longboard Pharmaceuticals Inc (LBPH) Stock
Based on ratings from 8 analysts Longboard Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 22 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on LBPH's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for LBPH is USD 61.97 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 36.
Unfortunately we do not have enough data on LBPH's stock to indicate if its overvalued.
The last closing price of LBPH's stock was USD 59.80.
The most recent market capitalization for LBPH is USD 2.33B.
Based on targets from 8 analysts, the average taret price for LBPH is projected at USD 61.97 over the next 12 months.
This means that LBPH's stock price may go up by +3.63% over the next 12 months.
We can't find any ETFs which contains Longboard Pharmaceuticals Inc's stock.
As per our most recent records Longboard Pharmaceuticals Inc has 50 Employees.
Longboard Pharmaceuticals Inc's registered address is 4275 Executive Square, La Jolla, CA, United States, 92037.
You can get more information about it from Longboard Pharmaceuticals Inc's website at https://www.longboardpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Longboard Pharmaceuticals Inc (LBPH) Stock
Based on ratings from 8 analysts Longboard Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 22 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on LBPH's stock to indicate if its a good dividend stock.
Based on targets from 8 analysts, the average taret price for LBPH is USD 61.97 over the next 12 months. The maximum analyst target price is USD 90 while the minimum anlayst target price is USD 36.
Unfortunately we do not have enough data on LBPH's stock to indicate if its overvalued.
The last closing price of LBPH's stock was USD 59.80.
The most recent market capitalization for LBPH is USD 2.33B.
Based on targets from 8 analysts, the average taret price for LBPH is projected at USD 61.97 over the next 12 months.
This means that LBPH's stock price may go up by +3.63% over the next 12 months.
We can't find any ETFs which contains Longboard Pharmaceuticals Inc's stock.
As per our most recent records Longboard Pharmaceuticals Inc has 50 Employees.
Longboard Pharmaceuticals Inc's registered address is 4275 Executive Square, La Jolla, CA, United States, 92037.
You can get more information about it from Longboard Pharmaceuticals Inc's website at https://www.longboardpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LBPH !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
